Nursing · Independent exam preparation
TCTCN™ Preparation Guide: Transplantation and Cellular Therapy Nursing Study Guide
Practise transplant selection, safe cell administration, and recognition of GVHD, sepsis, CRS, and neurotoxicity through focused TCTCN nursing cases and drills.
By CertMedbry · Updated 27 October 2026
Practise distinguishing treatment mechanisms, protecting patient-specific cellular products, recognizing urgent complications, and teaching patients and caregivers across recovery. This selective guide develops 60 substantive concepts across all six 2026 TCTCN domains. The official ONCC Test Content Outline defines the full examination scope, including topics requiring further study beyond these concepts.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Is TCTCN a different examination pathway from BMTCN?
ONCC renamed its existing Blood and Marrow Transplant Certified Nurse program Transplantation and Cellular Therapy Certified Nurse beginning January 2026. BMTCN examinations continued through December 2025. The updated outline increases cellular therapy coverage; the names do not identify two separate current certification pathways.
ONCC Changing Name of BMTCN® Certification to TCTCN™ · BMTCN® to TCTCN™ Name Change FAQ
What nursing level, patient populations, and jurisdictions does this guide address?
This guide addresses the TCTCN RN specialty examination for HSCT or cellular therapy nursing with adult or pediatric patients. It is separate from ONCC's Advanced Oncology Certified Nurse Practitioner examination. Standard eligibility requires an active, unencumbered RN license in the United States, its territories, or Canada, plus the specified experience, specialty practice, and education. The manual describes a separate license-equivalency process and limited testing period for international candidates.
Transplantation and Cellular Therapy Certified Nurse (TCTCN™) · 2026 ONCC Test Registration Manual
Which blueprint applies, and what are its domain weights?
The 2026 TCTCN Test Content Outline, copyright 2025, reflects the 2024 role delineation study. The 2026 registration manual is valid January 1, 2026; the standalone outline does not separately state an effective date. The domains are Foundations of HSCT and Cellular Therapy 22%; HSCT and Cellular Therapy Process and Administration 22%; Post-HSCT Management and Education 22%; Post-Cellular Therapy Management and Education 22%; Quality of Life 8%; and Professional Performance 4%.
2026 TCTCN™ Test Content Outline · 2026 ONCC Test Registration Manual
How many questions are scored, and how many are pretest questions?
The TCTCN section of the 2026 manual specifies 165 multiple-choice questions: 125 scored questions and 40 unscored pretest or experimental questions. Candidates cannot identify the pretest questions. These figures are specific to TCTCN; figures for another ONCC credential should not be substituted.
How long is the examination session?
The manual specifies a three-hour session, including 15 minutes for a computer-based tutorial before the examination and a post-test survey. There are no scheduled breaks, and the timer continues during a candidate-initiated break. Plan pacing around the complete session rather than assuming three uninterrupted hours solely for answering questions.
How is the examination delivered, and is it adaptive?
The manual verifies computer-based delivery at PSI test centers. An Authorization to Test generally provides a 90-day testing window; international testing has separate arrangements. The cited manual does not explicitly characterize the examination algorithm as adaptive or nonadaptive, and it does not establish remote-proctored delivery. These drills are independent practice questions.
What item styles and drug names should candidates expect?
ONCC describes a question or incomplete statement followed by four answer options, with one correct answer. Its current TCTCN page states that examinations use generic drug names. The learning test here follows that four-option, single-best-answer structure.
2026 ONCC Test Registration Manual · Transplantation and Cellular Therapy Certified Nurse (TCTCN™)
How should this selective guide be used with official and clinical references?
Use the official outline to identify the full scope, including NK cells, bispecific antibodies, gene therapy, accreditation, and complications not developed exhaustively here. The concepts are allocated 13/13/13/13/5/3 across the six domains; the questions and flashcards each use 4/4/5/4/2/1. Clinical references support clinical principles, while the outline establishes examination scope. CDC and FDA statements describe United States guidance; eviQ provides Australian clinical guidance.
2026 TCTCN™ Test Content Outline · Altered Immunocompetence · KYMRIAH: Package Insert and Medication Guide · Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
TCTCN™ is ONCC's registered-nurse specialty certification, renamed from BMTCN® in January 2026. This independent educational guide addresses adult and pediatric transplantation and cellular therapy nursing; its original learning questions are not official ONCC items or a prediction of examination performance.
Outline used: 2026 TCTCN™ Test Content Outline, copyright 2025, corroborated by the 2026 ONCC Test Registration Manual valid January 1, 2026; based on the 2024 role delineation study. ONCC explicitly renamed BMTCN® to TCTCN™ beginning January 2026. The assigned BMTCN workbook slug is preserved for this same renamed certification program.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Foundations of HSCT and Cellular Therapy22%
1.How do blood cell functions explain different consequences of pancytopenia?
Hematopoietic stem cells replenish blood cell populations with different protective functions. Red cells transport oxygen, platelets support hemostasis, and white cells contribute to immune defense. Suppression of several populations therefore creates simultaneous problems rather than one generic consequence of a low blood count. Assess the affected lineage together with symptoms: falling hemoglobin can accompany exertional intolerance, thrombocytopenia increases bleeding concerns, and neutropenia changes the urgency of infection assessment.
Apply it
A patient after conditioning reports breathlessness when walking and develops gingival bleeding. Review hemoglobin and platelets separately, assess respiratory status and bleeding severity, and avoid attributing both findings to neutropenia simply because the total white count is low.
Common pitfall: A recovering total white count does not establish recovery of red cells, platelets, or effective immunity. Each population requires its own interpretation.
2.Why can immune protection remain impaired after neutrophil recovery?
Immune competence includes cellular defenses and antibody-mediated protection, so a normal neutrophil count describes only part of recovery. Treatment may leave lymphocyte function, B-cell populations, immunoglobulins, or vaccine-derived protection impaired. The practical distinction is between numerical recovery of one cell population and functional recovery of the immune system. Infection prevention and immunization decisions must account for ongoing immunosuppression and the specific immune deficit rather than a reassuring complete blood count alone.
Apply it
A transplant recipient with a normal neutrophil count asks to stop infection precautions while still receiving treatment for GVHD. Explain that count recovery does not measure every immune function and review the continuing prevention plan with the transplant team.
Common pitfall: Using the absolute neutrophil count as a universal measure of immune recovery overlooks antibody deficiency, impaired lymphocyte function, and effects of immunosuppressive treatment.
Stem Cell and Bone Marrow Transplants for Cancer · Altered Immunocompetence
3.What does HLA matching measure when selecting an allogeneic donor?
Human leukocyte antigens are inherited markers involved in immune recognition. Donor-recipient HLA compatibility influences whether immune cells recognize the graft or recipient tissues as foreign. High-resolution typing can identify clinically important allele differences missed by less precise matching. HLA compatibility is distinct from ABO blood group compatibility and from being a relative. A sibling relationship makes matching possible, but actual typing determines compatibility; an unrelated donor may provide a suitable HLA match.
Apply it
A family assumes that a sibling with the patient's blood type must be the preferred donor. Explain why HLA testing remains necessary and why sharing an ABO group cannot establish the immunologic match needed for donor selection.
Common pitfall: Neither family relationship nor matching blood type substitutes for HLA typing. These features answer different questions about inheritance, immune compatibility, and transfusion planning.
Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
4.How do autologous and allogeneic transplants differ in therapeutic purpose?
An autologous transplant returns the patient's own hematopoietic stem cells, commonly restoring blood production after intensive treatment. An allogeneic transplant uses another person's cells and can provide both hematopoietic replacement and donor immune effects. These differences change education about donor selection, rejection, and GVHD. Autologous rescue does not provide the same donor-derived graft-versus-leukemia effect. Stem cell source and donor relationship are separate descriptors: peripheral blood cells can be used in either transplant type.
Apply it
Two patients receive peripheral blood stem cells, but one receives previously collected personal cells and the other receives a donor product. Identify the first transplant as autologous and explain why their donor immune complication discussions differ.
Common pitfall: Calling every peripheral blood stem cell infusion autologous confuses the collection source with the donor relationship, which determines important immunologic risks and benefits.
5.Why can donor immunity produce both graft-versus-leukemia effects and GVHD?
Donor immune cells can recognize residual malignant cells and contribute to disease control through a graft-versus-leukemia or graft-versus-tumor effect. The same broad capacity for alloreactivity can target healthy recipient tissues, producing GVHD. These outcomes are related but not interchangeable: clinically significant GVHD is harmful and is not required as proof of effective cancer control. Nursing assessment must preserve the distinction between a therapeutic immune objective and tissue injury needing evaluation and treatment.
Apply it
A patient says a new rash must be beneficial because it proves donor cells are attacking leukemia. Explain the potential donor antitumor effect while arranging assessment of the rash rather than presenting tissue injury as a desired treatment endpoint.
Common pitfall: Describing GVHD as necessary evidence of treatment success can discourage symptom reporting and medication adherence. Beneficial antitumor immunity does not make organ injury acceptable.
Stem Cell and Bone Marrow Transplants for Cancer · Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
6.How do transplant goals change for nonmalignant blood disorders?
HSCT can treat nonmalignant disorders by replacing defective or inadequate hematopoiesis or immune function. In conditions such as aplastic anemia or sickle cell disease, the central objective is functional correction rather than elimination of malignant cells. This matters when interpreting donor chimerism and immune effects. Some nonmalignant disorders can improve with stable mixed donor-recipient hematopoiesis, whereas donor immune attack on normal tissues adds harm without an antileukemia benefit to pursue.
Apply it
A child transplanted for a nonmalignant disorder has stable mixed chimerism and improved disease manifestations. Explain why the transplant team evaluates functional correction and serial trends rather than automatically labeling any recipient-derived cells as cancer relapse.
Common pitfall: Applying leukemia-focused assumptions to every transplant can misclassify stable mixed chimerism and overstate the value of donor alloreactivity in a nonmalignant disease.
Stem Cell and Bone Marrow Transplants for Cancer · Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
7.Which distinctions matter among cell sources and alternative donors?
Peripheral blood, bone marrow, and umbilical cord blood describe hematopoietic cell sources. Matched related, matched unrelated, mismatched unrelated, and haploidentical describe donor relationships or HLA compatibility. In allogeneic transplantation, peripheral blood generally provides faster hematopoietic recovery than marrow but carries greater chronic graft-versus-host disease (GVHD) risk. Marrow generally has lower chronic GVHD risk than peripheral blood. Cord blood generally produces slower hematopoietic recovery and immune reconstitution, with associated infection and nonengraftment concerns. These comparisons describe general patterns: outcomes also depend on HLA matching, cell dose, graft manipulation, conditioning, GVHD prevention, and the recipient's disease and clinical condition.
Apply it
A handoff describes a graft only as 'matched unrelated.' Clarify its cell source. For an unrelated peripheral blood graft, teach the potential for faster blood count recovery alongside chronic GVHD surveillance. For cord blood, explain the generally slower blood count and immune recovery and the resulting need for sustained infection precautions and engraftment monitoring. Blood count recovery alone does not establish full immune recovery.
Common pitfall: Do not treat 'allogeneic,' 'unrelated,' and 'cord blood' as equivalent labels or assume one source is universally superior. A matched donor does not eliminate source-related risks, and an adequate cell dose and appropriate recipient context remain essential when comparing graft options.
2026 TCTCN™ Test Content Outline · Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
8.How do CAR T cells recognize their intended targets?
CAR T-cell therapy modifies T cells to express a chimeric antigen receptor that recognizes a selected cell-surface target. The cells are expanded and infused to provide directed immune activity. Target expression, rather than malignant status alone, determines which cells may be affected. For a CD19-directed product, normal B cells can also be depleted. This explains why antitumor activity and prolonged immune deficiency may coexist and why product-specific target information belongs in patient education.
Apply it
A patient receiving CD19-directed CAR T cells asks why normal B cells might decrease despite the treatment's precision. Explain that the receptor recognizes CD19 on both malignant and normal B cells, creating a predictable immune consequence.
Common pitfall: Calling CAR T cells cancer-exclusive overlooks shared target expression on normal tissues. Target specificity does not guarantee that only malignant cells will be affected.
T-cell Transfer Therapy · KYMRIAH: Package Insert and Medication Guide
9.How does TIL therapy differ from CAR T-cell therapy?
Tumor-infiltrating lymphocyte therapy begins with lymphocytes obtained from tumor tissue and expands cells capable of recognizing that tumor. CAR T-cell therapy instead introduces a receptor designed to recognize a selected surface target. Both are adoptive T-cell approaches, but their starting material and recognition strategy differ. Do not transfer the collection pathway, target-related effects, or toxicity assumptions of one product directly to another simply because both treatments return expanded immune cells.
Apply it
A patient scheduled for tumor tissue procurement expects routine blood collection to supply the entire TIL manufacturing process. Explain why tumor-derived lymphocytes are needed and contrast that starting material with the blood-derived T cells used for conventional autologous CAR manufacturing.
Common pitfall: Assuming every adoptive T-cell treatment involves insertion of a CAR obscures the defining feature of TIL therapy: expansion of tumor-associated lymphocytes with existing recognition.
10.Why might donor lymphocyte infusion be considered after allogeneic HSCT?
Donor lymphocyte infusion supplies additional donor immune cells after allogeneic transplantation to strengthen donor immune activity. It may be considered for selected relapse or chimerism concerns rather than as routine stem cell replacement. Its potential benefit depends on disease and transplant context, and stronger alloreactivity can cause GVHD. Serial chimerism and disease assessments guide the team's reasoning; the nurse should distinguish an immune intervention from another collection of hematopoietic stem cells.
Apply it
After allogeneic HSCT, a patient with falling donor chimerism hears that DLI is being discussed. Explain its immune purpose and the need to monitor for GVHD, while avoiding any promise that the intervention will necessarily restore durable disease control.
Common pitfall: DLI is not synonymous with a second stem cell transplant. Increasing donor immune activity may help selected patients but also creates clinically important GVHD risk.
Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
11.How do NK-cell therapy, T-cell-engaging bispecific antibodies, and gene therapy act?
NK cells integrate activating signals from stressed targets with inhibitory signals from HLA class I; reduced inhibitory recognition can favor killing when activating signals are sufficient. They release cytotoxic granules that kill target cells. See the [NK recognition study](https://doi.org/10.1073/pnas.2503259122) and [NCI NK-cell description](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/natural-killer-cell). Teclistamab binds CD3 on T cells and BCMA on plasma cells, bringing them together to induce T-cell cytotoxicity; it is an antibody rather than an infused cell product. See the [NCI mechanism description](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/teclistamab). Gene addition supplies a therapeutic gene: lovotibeglogene autotemcel enables production of antisickling hemoglobin. Gene editing changes endogenous DNA: exagamglogene autotemcel edits the BCL11A erythroid enhancer to increase fetal hemoglobin and reduce sickling. These approaches improve hemoglobin function through different genetic mechanisms. See the [FDA gene-therapy comparison](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease) and [exagamglogene mechanism](https://www.fda.gov/media/174615/download).
Apply it
Compare the administered material and its action: NK cells perform cytotoxic killing, teclistamab bridges an existing T cell to a BCMA-expressing target, and modified hematopoietic stem cells produce erythroid descendants with therapeutic hemoglobin effects.
Common pitfall: Gene addition does not necessarily repair the original mutation, and gene editing need not directly correct that mutation. Editing a regulatory element can compensate by increasing fetal hemoglobin.
What is Gene Therapy? | FDA · 2026 TCTCN™ Test Content Outline
12.Which findings determine recipient suitability beyond the diagnosis?
A potentially responsive diagnosis does not by itself establish treatment suitability. Evaluation considers disease status, prior therapy, ability to tolerate the preparative regimen, organ function, comorbidities, and availability of an appropriate product or donor. Practical support also affects whether monitoring and urgent access can be delivered reliably. The nursing contribution is to identify modifiable barriers and communicate meaningful findings rather than treating age, diagnosis, or one laboratory result as a complete eligibility decision.
Apply it
A patient has a transplant-responsive malignancy but worsening breathlessness and no reliable transport to follow-up. Escalate the clinical symptom and involve care coordination early, so physiologic readiness and access barriers are assessed before the treatment schedule advances.
Common pitfall: A suitable disease indication does not override active clinical deterioration. Conversely, a practical support barrier should trigger problem-solving rather than an unsupported assumption of permanent ineligibility.
Stem Cell and Bone Marrow Transplants for Cancer · 2026 TCTCN™ Test Content Outline
13.Why does a matched donor still need independent health evaluation?
A donor match answers a compatibility question, not whether collection is safe or fully understood. Donor evaluation includes health history, physical assessment, laboratory testing, and education about the collection method and expected recovery. A related donor remains an individual with independent interests and a right to ask questions. Nursing assessment should identify symptoms or concerns without assuming that the recipient's urgent need justifies overlooking donor health or pressure within the family.
Apply it
A matched sibling minimizes a new illness because the family fears delaying transplantation. Arrange private discussion and prompt donor-team review, explaining that accurate health information protects both people and is essential even when HLA compatibility has already been established.
Common pitfall: Compatibility does not equal medical clearance or voluntary agreement. Family urgency can conceal donor concerns unless the donor has a genuine opportunity to speak independently.
Peripheral Blood Stem Cell Donation Process Overview · 2026 TCTCN™ Test Content Outline
HSCT and Cellular Therapy Process and Administration22%
14.How does filgrastim support peripheral blood stem cell collection?
Filgrastim increases the availability of blood-forming stem cells in circulating blood, allowing collection by apheresis. It prepares the donor for collection; it does not perform HLA matching or directly collect the cells. Bone or muscle aching can occur during mobilization and should be assessed in context. Education should connect the medication's purpose with the later procedure so donors understand why injections precede a collection that resembles other extracorporeal blood component procedures.
Apply it
A donor asks why injections are necessary when the cells will be removed from an arm vein. Explain that mobilization increases circulating stem cell availability and review expected aches, reporting instructions, and the planned apheresis appointment.
Common pitfall: Do not explain mobilization as increasing red cell oxygen delivery or improving donor-recipient HLA matching. Its collection-related purpose is increasing stem cells available in blood.
15.What does tingling during apheresis suggest?
Apheresis removes blood, separates the desired cell component, and returns other components to the donor. Anticoagulant exposure during the procedure can produce tingling around the mouth or in the fingers, a cue to assess for citrate-related effects on ionized calcium. The symptom should be reported promptly to collection staff rather than dismissed as anxiety. Its timing during extracorporeal circulation helps distinguish this problem from the musculoskeletal aching commonly associated with preceding mobilization.
Apply it
During collection, a donor reports new lip and fingertip tingling after feeling well at the start. Notify the apheresis clinician and assess the symptoms promptly instead of assuming the donor is merely nervous about the equipment.
Common pitfall: A donor's anxiety may coexist with a physiologic collection reaction. Reassurance alone is inadequate when characteristic sensory symptoms appear during anticoagulant exposure in apheresis.
16.How does marrow harvest differ from peripheral blood collection?
Peripheral blood stem cell collection uses apheresis to separate circulating cells after mobilization. Marrow donation is a surgical collection from the hip region rather than collection from the spinal cord. These different routes require different preparation and recovery explanations. A donor should understand the actual planned procedure, including whether surgical and anesthesia assessment is needed, instead of receiving interchangeable instructions for every form of hematopoietic cell donation.
Apply it
A donor scheduled for marrow harvest says they expect to sit beside an apheresis machine. Clarify the planned surgical collection from the pelvic bone and connect the donor with the collection team for the appropriate preparation and recovery instructions.
Common pitfall: The word 'marrow' does not mean spinal cord collection. Confusing the two can create avoidable fear and undermine accurate understanding of the donation procedure.
17.Why must collection targets match the intended cellular product?
Collection is designed around the cells needed for the intended treatment. HSCT requires blood-forming stem cells, conventional autologous CAR T manufacturing begins with T cells, and TIL therapy uses lymphocytes obtained from tumor tissue. Similar equipment or intravenous delivery does not make these starting materials interchangeable. Verify the intended product and collection purpose before teaching or coordinating care, because a successful collection for one pathway does not establish that another product can be manufactured.
Apply it
A patient previously collected for autologous HSCT assumes those stored cells can automatically supply a new CAR T product. Explain that the therapies require different cell populations and confirm the manufacturing pathway before changing any collection appointments.
Common pitfall: A previous successful cell collection does not prove that the right starting material exists for a different therapy. Collection adequacy is specific to the intended product.
Stem Cell and Bone Marrow Transplants for Cancer · T-cell Transfer Therapy
18.How does conditioning intensity affect marrow and immune suppression?
Conditioning can suppress recipient immunity, treat malignancy, and support donor engraftment. Myeloablative regimens cause profound, irreversible marrow suppression requiring stem cell rescue. Reduced-intensity and nonmyeloablative approaches reduce direct myelosuppression and rely more heavily on donor immune effects, although substantial risks remain. Intensity is therefore a biologic description of treatment effects, not a simple measure of how serious the overall transplant is or whether infection and GVHD surveillance can be relaxed.
Apply it
A patient offered reduced-intensity allogeneic HSCT believes follow-up will be minimal because treatment is 'lighter.' Explain its greater reliance on donor immunity and why immune suppression, GVHD, and infection still require close monitoring after the preparative regimen.
Common pitfall: Reduced conditioning intensity does not mean absent immune suppression or negligible transplant risk. It changes the balance of treatment mechanisms rather than removing complications altogether.
Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
19.Why are reduced-toxicity and reduced-intensity conditioning different terms?
Reduced-toxicity regimens aim to lessen selected toxic effects while potentially retaining myeloablative marrow effects. Reduced-intensity conditioning describes a different category of preparative intensity. The NCI pediatric allogeneic summary identifies regimens that are myeloablative despite being described as reduced toxicity. The discriminating question is whether the regimen's marrow effect remains myeloablative, not whether its name sounds gentler. Nursing expectations for cytopenia and rescue must follow the actual regimen classification.
Apply it
A handoff describes a child's regimen as reduced toxicity, and a learner predicts only mild count suppression. Review the regimen's myeloablative classification before planning education, emphasizing that less organ toxicity does not necessarily mean less marrow ablation.
Common pitfall: Using 'reduced toxicity' as a synonym for 'reduced intensity' can produce incorrect expectations about marrow suppression, stem cell support, and the duration of hematologic vulnerability.
Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
20.How does lymphodepletion differ from interim disease-control treatment?
Before adoptive T-cell infusion, lymphodepleting treatment reduces existing immune cells and helps transferred cells function more effectively. Treatment given while a cellular product is being manufactured may instead be intended primarily to control disease during the waiting period. These purposes can overlap, but the treatments are not automatically interchangeable. The prescribed lymphodepletion-to-infusion sequence remains product specific, so previous chemotherapy does not establish that the patient has completed the required preparative step.
Apply it
A patient received chemotherapy while awaiting CAR manufacturing and assumes no further preparation is needed. Clarify whether that treatment controlled disease or fulfilled the prescribed lymphodepleting regimen, then reconcile the actual infusion sequence with the cellular therapy team.
Common pitfall: Any chemotherapy before CAR T infusion is not automatically lymphodepletion. Purpose, regimen, clinical condition, and timing determine whether the required preparative treatment has been completed.
T-cell Transfer Therapy · KYMRIAH: Package Insert and Medication Guide
21.When should new clinical deterioration interrupt planned cellular product preparation?
A scheduled infusion does not replace reassessment of clinical readiness. The tisagenlecleucel label identifies unresolved serious chemotherapy reactions, active uncontrolled infection, active GVHD, and worsening leukemia burden after lymphodepletion as reasons to delay infusion. Because thawing creates a short administration window, readiness concerns should be addressed before product preparation. The nurse connects current physiology, product-specific precautions, and manufacturing coordination rather than treating the calendar appointment as an instruction to proceed regardless of change.
Apply it
Before a planned tisagenlecleucel thaw, the patient develops new hypotension and rigors. Hold product preparation, escalate urgent clinical assessment, and notify the processing team so a time-sensitive product is not thawed while infusion readiness remains unresolved.
Common pitfall: Product arrival and completed lymphodepletion do not guarantee readiness. Proceeding solely to preserve the schedule can expose a clinically unstable patient to avoidable treatment risk.
22.Why does cryopreservation change infusion preparation and monitoring?
Cryopreservation allows cellular products to be stored for later use while introducing handling requirements associated with freezing, thawing, and cryoprotectants such as DMSO. Fresh and frozen products therefore cannot share every preparation assumption. Thawing must be coordinated with recipient readiness and the product's permitted administration window. DMSO exposure also creates potential infusion symptoms, so baseline assessment and observation during administration are necessary even when the intended therapeutic cells are autologous.
Apply it
A nurse proposes thawing a cryopreserved product early to simplify a busy shift. Check the product instructions and coordinate with the laboratory and bedside team before thawing, because convenience cannot determine the acceptable interval before administration.
Common pitfall: Autologous identity does not eliminate preservative-related reactions or protect cells from mishandling. Product viability and recipient monitoring remain separate safety concerns during administration.
Hypersensitivity Reaction to Dimethyl Sulfoxide (DMSO) · KYMRIAH: Package Insert and Medication Guide
23.How does patient-specific product verification prevent a catastrophic mismatch?
A patient-specific autologous cellular product must remain linked to its intended recipient from collection through administration. Tisagenlecleucel instructions require matching patient identifiers to every infusion bag before preparation and again before infusion. Product name, diagnosis, or ABO group cannot substitute for these identifiers. A discrepancy requires stopping the preparation or administration process and resolving the mismatch through the responsible team, because a living product cannot be treated as interchangeable inventory.
Apply it
The product name and dose look correct, but the collection identifier does not match the patient's records. Keep the product from being administered and contact the laboratory and treatment team to reconcile the identifiers before any further preparation.
Common pitfall: A familiar name, compatible blood group, or correct product strength does not establish patient identity. Partial agreement cannot compensate for an unresolved identifier discrepancy.
24.Which administration practices can unintentionally remove or damage therapeutic cells?
Cellular products contain living therapeutic material, making product-specific handling essential. Tisagenlecleucel instructions prohibit a leukocyte-depleting filter and prohibit washing, spinning down, or resuspending the product before infusion. Such actions cannot be added merely because they resemble familiar blood product or laboratory practices. Bag integrity, visible clumps, thaw coordination, and complete administration also matter. The transferable principle is to protect the intended cells while following the exact handling instructions for the identified product.
Apply it
A colleague prepares a leukocyte-depleting filter for tisagenlecleucel because it is routinely used with another blood product. Stop and replace that setup with the prescribed administration system before infusion, explaining that the therapeutic material consists of modified T cells.
Common pitfall: Familiar transfusion equipment is not automatically appropriate for cellular therapy. A process intended to remove leukocytes can conflict directly with delivery of therapeutic immune cells.
25.How should a suspected reaction during cryopreserved-cell infusion be managed initially?
Stop the infusion immediately and assess airway, breathing, and circulation. Throat tightness, wheezing, hypoxia, or hypotension after infusion exposure warrants emergency treatment for suspected anaphylaxis, even without hives. Activate emergency assistance and promptly administer intramuscular epinephrine (adrenaline) into the outer mid-thigh under the emergency protocol; do not delay epinephrine while awaiting diagnostic confirmation. Provide oxygen, maintain vascular access, and give intravenous isotonic crystalloid for hypotension as indicated. Position a hypotensive patient flat with legs elevated; do not allow standing or walking. Repeat epinephrine according to the emergency protocol if symptoms persist. Preserve remaining product and equipment for evaluation after immediate treatment has begun.
Apply it
Minutes into a thawed stem cell infusion, a patient develops throat tightness, wheezing, and falling blood pressure without a rash. These respiratory and circulatory findings support suspected anaphylaxis. Stop exposure, activate the emergency response, and promptly give intramuscular epinephrine while providing oxygen, appropriate positioning, and circulatory support. Slowing the infusion or administering an antihistamine alone leaves the potentially fatal reaction inadequately treated.
Common pitfall: Premedication does not reliably prevent anaphylaxis. Antihistamines do not treat its airway obstruction or shock, and corticosteroids must not replace or delay epinephrine. Bronchodilators may supplement treatment of persistent wheeze but do not correct upper airway obstruction or hypotension. A known DMSO exposure must not lead clinicians to dismiss severe symptoms as an expected preservative effect.
Hypersensitivity Reaction to Dimethyl Sulfoxide (DMSO) · ASCIA Guidelines - Acute Management of Anaphylaxis - Australasian Society of Clinical Immunology and Allergy (ASCIA)
26.How do major and minor ABO mismatches create different hemolytic risks?
ABO compatibility concerns red-cell antigens and antibodies, separately from HLA matching. In major mismatch, recipient antibodies recognize donor red-cell antigens; incompatible red cells in the graft can undergo hemolysis. In minor mismatch, donor plasma antibodies or antibodies subsequently produced by donor lymphocytes can attack recipient red cells, including delayed passenger-lymphocyte hemolysis. Red-cell depletion addresses incompatible graft red cells, whereas plasma reduction addresses transferred antibodies. Processing depends on antibody titers, graft source, and component volumes. Transfusion selection also changes with transplant phase: red cells must be compatible with both donor and recipient, and plasma and platelets compatible with both are preferred. See the [2024 EBMT transfusion-support chapter](https://www.ncbi.nlm.nih.gov/books/NBK608283/).
Apply it
For a group O recipient receiving a group A graft, identify recipient anti-A as the major-mismatch direction. For a group A recipient receiving a group O graft, identify donor anti-A as the minor-mismatch direction. Verify the phase-specific blood-bank instructions.
Common pitfall: Neither automatic red-cell depletion of every mismatched graft nor immediate switching of all transfusions to the donor group is a universal rule.
Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®) · 2026 TCTCN™ Test Content Outline
Post-HSCT Management and Education22%
27.Why are leukocyte reduction and irradiation separate transfusion requirements?
Leukocyte reduction decreases residual donor leukocytes, reducing febrile reactions, leukocyte alloimmunization, and transfusion-transmitted CMV risk. Irradiation prevents viable donor T cells in cellular blood components from proliferating and causing transfusion-associated GVHD. Leukocyte reduction alone does not reliably provide that protection. For HSCT recipients, verify the required irradiation or an accepted lymphocyte-inactivating alternative, leukocyte reduction, and the designated CMV-risk strategy. Duration depends on transplant type and immune status. These requirements concern supportive blood components; therapeutic stem-cell grafts and CAR T products require their own handling instructions. See the [2024 EBMT transfusion-support chapter](https://www.ncbi.nlm.nih.gov/books/NBK608283/).
Apply it
A leukocyte-reduced red-cell unit arrives for an allogeneic recipient whose order requires irradiated components. Confirm irradiation before transfusion; a leukocyte-reduced label does not establish that donor T-cell proliferation has been prevented.
Common pitfall: Do not irradiate or leukocyte-filter a therapeutic cellular graft by applying supportive-transfusion rules. Those actions could destroy or remove the intended therapeutic cells.
2026 TCTCN™ Test Content Outline · KYMRIAH: Package Insert and Medication Guide
28.How is the absolute neutrophil count calculated and interpreted with fever?
When the differential reports percentages, ANC equals the white blood cell count multiplied by the combined fraction of segmented neutrophils and bands. Keep units consistent. In current eviQ guidance, temperature at least 38.0°C with ANC below 0.5 × 10^9/L meets its neutropenic fever definition; a higher ANC below 1.0 × 10^9/L also qualifies if predicted to fall below 0.5 within 48 hours. Recognizing the emergency matters more than completing arithmetic before escalation.
Apply it
A recipient has WBC 1.2 × 10^9/L, neutrophils 25%, bands 5%, and temperature 38.3°C. Calculate ANC as 1.2 × 0.30 = 0.36 × 10^9/L and initiate urgent neutropenic fever assessment.
Common pitfall: Adding percentages to the total white count or using neutrophils alone when bands are supplied produces the wrong ANC. Do not delay emergency assessment for calculation.
Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
29.When should sepsis be suspected despite the absence of fever?
Immunocompromised patients can develop sepsis without fever, including during corticosteroid or immunomodulatory treatment. New hypotension, altered mental status, tachypnea, reduced urine output, or other organ dysfunction warrants urgent assessment. Obtain appropriate cultures promptly when feasible, but difficulty obtaining samples must not delay empiric antimicrobial treatment. Temperature is one observation within a broader physiologic assessment. A low or normal reading cannot safely exclude infection in an unwell transplant recipient.
Apply it
A neutropenic recipient taking corticosteroids becomes confused and hypotensive with temperature 36.7°C. Activate urgent sepsis assessment and treatment rather than waiting for a fever or the next routine laboratory collection to establish that the patient is ill.
Common pitfall: Waiting for the classic fever threshold can miss sepsis in an immunosuppressed patient. Clinical deterioration and organ dysfunction can be the most important initial cues.
Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
30.Which manifestations warrant assessment for acute GVHD?
Acute GVHD commonly involves skin, gastrointestinal tract, and liver manifestations. Relevant findings include a new erythematous rash, persistent nausea or anorexia, diarrhea, abdominal pain, and increased bilirubin. These findings are not individually diagnostic because medication effects and infections can resemble GVHD. Document the pattern, severity, and trajectory while arranging evaluation of competing causes. Quantifying stool output and describing rash distribution provide more useful assessment information than labeling every post-transplant symptom as expected.
Apply it
An allogeneic recipient develops a spreading rash and increasing watery stool output. Record distribution, stool volume, associated symptoms, and recent medication changes, then escalate evaluation for GVHD and alternative causes instead of treating the findings as routine recovery.
Common pitfall: Diarrhea alone does not prove GVHD. Infection and treatment toxicity remain important alternatives, so symptom control must not replace assessment of the underlying cause.
31.Which manifestations distinguish chronic GVHD from late acute GVHD?
GVHD classification follows manifestations rather than day 100 alone. Under the NIH 2014 diagnosis criteria, published in 2015, diagnostic chronic features include sclerotic skin changes and lichen planus-like skin or oral changes. Distinctive findings, such as oral dryness, require appropriate confirmatory evidence when no diagnostic manifestation is present. Infection, medication effects, and other causes must be excluded. An ordinary maculopapular rash, diarrhea, or cholestatic liver abnormality can occur in acute GVHD and does not independently establish chronic disease. Chronic diagnostic features together with acute manifestations support overlap chronic GVHD. See the [NIH diagnosis and staging criteria](https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/).
Apply it
At day 145, an acute-pattern rash and diarrhea without chronic features can represent late acute GVHD. A comparable patient with diagnostic skin sclerosis plus acute gastrointestinal manifestations can instead meet the overlap chronic phenotype after competing causes are assessed.
Common pitfall: Neither a late date nor multiple affected organs establishes chronic GVHD. A distinctive finding alone is also insufficient without the required confirmation.
32.Why must immunosuppressive treatment changes be deliberate after HSCT?
Immunosuppressive treatment helps prevent or control donor immune injury but also contributes to infection vulnerability and other treatment burdens. Stopping because symptoms improve can permit renewed alloreactivity, while persisting symptoms may represent active inflammation, fixed damage, or another cause. A planned taper therefore requires clinical interpretation rather than a patient's impression that the medicine is no longer needed. Nursing education should connect adherence and symptom reporting with the team's assessment of disease activity and toxicity.
Apply it
A recipient whose rash has improved plans to stop GVHD treatment because of unpleasant effects. Ask what has been taken, assess the adverse effects, and contact the treatment team to address the burden without an unsupervised interruption.
Common pitfall: Symptom improvement during treatment does not prove that GVHD has resolved independently of treatment. Abrupt self-discontinuation and automatic escalation both bypass assessment of actual disease activity.
Stem Cell and Bone Marrow Transplants for Cancer · EBMT–NIH–CIBMTR Task Force Position Statement on Standardized Terminology and Guidance for GVHD Assessment
33.Why does mucosal injury require more than pain assessment?
Preparative treatment can injure the oral and gastrointestinal mucosa, producing pain, reduced intake, and impaired medication tolerance. Mucosal barrier damage also increases infectious risk during neutropenia. Assess swallowing, hydration, nutritional intake, oral findings, and the ability to take essential medicines alongside pain severity. The decision is not simply whether discomfort is tolerable: a patient whose pain seems modest may still have clinically important dehydration, interrupted therapy, or an emerging infectious complication.
Apply it
A recipient reports mild mouth pain but has stopped drinking and missed oral medicines for a day. Evaluate intake, hydration, mucosal findings, and medication tolerance, then coordinate symptom and nutrition support rather than relying on the low pain rating.
Common pitfall: A low pain score does not establish adequate nutrition or safe medication intake. Treating discomfort alone can leave the functional consequences of mucosal injury unaddressed.
Stem Cell and Bone Marrow Transplants for Cancer · Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
34.How does hepatic sinusoidal injury produce SOS/VOD?
Sinusoidal obstruction syndrome begins with hepatic endothelial and related tissue injury after selected conditioning or anticancer treatments. Obstructed sinusoidal flow contributes to fluid retention and liver dysfunction. A concerning cluster includes rapid weight gain, ascites, painful hepatomegaly or right upper quadrant discomfort, and rising bilirubin. Monitor trends in weight, fluid balance, abdominal findings, liver tests, and organ function. The cluster should prompt timely evaluation rather than waiting for every possible feature or advanced multiorgan dysfunction.
Apply it
After conditioning, a recipient gains weight rapidly and develops abdominal distension, right upper quadrant pain, and rising bilirubin. Escalate assessment for SOS/VOD and review fluid and organ-function trends instead of attributing the whole pattern to routine intravenous hydration.
Common pitfall: Isolated fluid overload is a tempting explanation, but weight gain accompanied by liver pain, ascites, or bilirubin change requires assessment for a hepatic vascular complication.
Sinusoidal Obstruction Syndrome Associated with Anti-cancer Therapy
35.Which late pulmonary changes raise concern for bronchiolitis obliterans syndrome?
Bronchiolitis obliterans syndrome, a pulmonary chronic-GVHD manifestation, produces new airflow obstruction and may initially be asymptomatic. New exertional dyspnea, dry cough, wheeze, or declining spirometry warrants evaluation. NIH 2014 criteria include FEV1/VC below 0.7 or the age-appropriate lower limit, FEV1 below 75% predicted with at least a 10-percentage-point decline within less than two years, and exclusion of respiratory infection. The deficit must remain qualifying after bronchodilator assessment. Air trapping on expiratory CT or lung volumes provides additional support; established chronic GVHD elsewhere affects which supporting criteria are required. See the [NIH pulmonary criteria](https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/).
Apply it
A survivor with established skin chronic GVHD develops cough and an FEV1 decline from 91% to 70% predicted. Arrange prompt spirometry review, infection assessment, and pulmonary evaluation rather than attributing the change to deconditioning.
Common pitfall: Normal resting oxygen saturation does not exclude early BOS. Restrictive abnormalities require assessment for other pulmonary or chest-wall processes rather than automatic classification as BOS.
EBMT–NIH–CIBMTR Task Force Position Statement on Standardized Terminology and Guidance for GVHD Assessment · 2026 TCTCN™ Test Content Outline
36.How should antimicrobial prophylaxis match the immune deficit after HSCT?
Different prophylactic agents prevent different infections. Acyclovir or valacyclovir suppresses HSV/VZV reactivation in appropriate at-risk recipients; it does not provide Pneumocystis protection. Trimethoprim-sulfamethoxazole is preferred for Pneumocystis jirovecii prophylaxis when tolerated. In adults after allogeneic HSCT, eviQ recommends PJP prophylaxis from engraftment for at least six months and while immunosuppressive treatment continues. Assess adherence, kidney function, cytopenias, and intolerance; an alternative must preserve organism-specific protection. Antibacterial and antifungal prophylaxis is considered for profound, prolonged neutropenia, with additional fungal risk from GVHD treatment. See [eviQ PJP prophylaxis](https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/220-pneumocystis-jirovecii-pneumonia-pjp-prophyl) and [HSV/VZV prophylaxis](https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/1795-herpes-simplex-hsv-and-varicella-zoster-vir).
Apply it
An adult eight months after allogeneic HSCT plans to stop PJP prophylaxis because neutrophils recovered, although systemic GVHD treatment continues. Explain that the ongoing immunosuppressive risk remains relevant and reconcile the prevention plan.
Common pitfall: One antimicrobial does not cover every pathogen, and prophylaxis does not exclude breakthrough infection. Fever or organ dysfunction still requires urgent assessment.
Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management · 2026 TCTCN™ Test Content Outline
37.How should chronic GVHD assessment distinguish active injury from fixed deficits?
Chronic GVHD can cause inflammatory injury and lasting fibrosis. Diagnostic manifestations include sclerotic skin and lichen planus-like oral changes; distinctive manifestations need confirmation when no diagnostic feature is present. After diagnosis, persistent limitation does not independently establish ongoing inflammation. Compare new progression with established deficits, documenting organ findings and function separately. The EBMT–NIH–CIBMTR statement distinguishes active disease from controlled disease and persistent sequelae. The [NIH diagnosis and staging criteria](https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/) also emphasize attribution and exclusion of competing causes.
Apply it
A survivor has stable shoulder restriction from prior sclerosis and new lichen planus-like oral changes. Describe the established disability separately from the new manifestation so current activity and rehabilitation needs can each be assessed.
Common pitfall: An ordinary maculopapular rash alone does not diagnose chronic GVHD. Likewise, persistence of an old contracture does not prove that more immunosuppression will reverse it.
38.When can live MMR or varicella vaccination be considered after HSCT?
HSCT can diminish previous vaccine protection, so prior vaccination does not remove the need for a post-transplant immunization plan. CDC guidance permits consideration of MMR and varicella revaccination after at least 24 months when the recipient has no GVHD and is considered immunocompetent. Time alone is insufficient. Non-live vaccine schedules differ, and immunosuppressive therapy or recent immunoglobulin can affect decisions. Distinguish live-vaccine safety requirements from the timing and effectiveness considerations of non-live vaccines.
Apply it
A recipient 26 months after HSCT requests MMR while receiving treatment for active GVHD. Explain that passing the time threshold does not establish eligibility and arrange review of immune status and treatment before vaccination proceeds.
Common pitfall: Applying the 24-month threshold as automatic clearance overlooks GVHD and immune competence. A normal neutrophil count does not independently establish that a live vaccine is appropriate.
39.Why does long-term HSCT follow-up continue after disease remission?
Remission addresses the treated disease but does not eliminate delayed treatment consequences. HSCT survivors may develop organ injury, cataracts, reproductive effects, bone or muscle problems, and subsequent malignancies. Follow-up must connect prior exposures, current symptoms, chronic GVHD, and health maintenance needs. The discriminating principle is that a reassuring disease assessment answers a different question from survivorship surveillance. New symptoms warrant evaluation rather than automatic attribution to aging, deconditioning, or an expected permanent transplant effect.
Apply it
A survivor in remission develops progressive exercise intolerance and assumes nothing serious can be wrong because the last cancer assessment was reassuring. Encourage timely evaluation and review treatment exposures rather than equating disease remission with freedom from late complications.
Common pitfall: Disease-free status is not a substitute for organ and survivorship assessment. Late effects and new malignancies can emerge after apparently successful recovery from the original disease.
Stem Cell and Bone Marrow Transplants for Cancer · 2026 TCTCN™ Test Content Outline
Post-Cellular Therapy Management and Education22%
40.How does immune-cell activation produce cytokine release syndrome?
CRS occurs when activated therapeutic or responding immune cells release inflammatory mediators that produce systemic illness. Fever may be accompanied by tachycardia, hypotension, or respiratory compromise. The mechanism explains why a treatment designed to stimulate immune activity can also threaten perfusion and oxygenation. Recognize the temporal relationship to therapy, but do not treat it as diagnostic proof: infection and other causes can produce a similar presentation and require concurrent assessment.
Apply it
After CAR T infusion, a patient develops fever followed by falling oxygen saturation and blood pressure. Escalate assessment for inflammatory toxicity and impaired organ support while ensuring infectious causes are investigated rather than labeling the fever as harmless immune activation.
Common pitfall: CRS is not simply an expected fever that can be ignored. Progression in oxygenation or circulation indicates a clinically different problem from isolated temperature elevation.
T-cell Transfer Therapy · KYMRIAH: Package Insert and Medication Guide
41.Why must infection assessment continue when CRS is suspected?
CRS and infection share findings such as fever, hypotension, hypoxia, and altered clinical status, and they can occur together. A plausible inflammatory explanation does not exclude sepsis, particularly after lymphodepletion or with prolonged cytopenia. Obtain appropriate cultures and provide timely empiric antimicrobial treatment when indicated while the team evaluates and treats CRS. Neither a negative initial culture nor response to inflammatory treatment proves that infection was absent or that further surveillance is unnecessary.
Apply it
A neutropenic CAR T recipient develops fever on a day when CRS is common. Initiate the urgent fever assessment and prescribed infection management while notifying the cellular therapy team, instead of withholding antibiotics until inflammatory toxicity has been confirmed.
Common pitfall: Timing after infusion cannot distinguish CRS from sepsis reliably. Treating the two possibilities as mutually exclusive can delay necessary antimicrobials or miss simultaneous complications.
KYMRIAH: Package Insert and Medication Guide · Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
42.How does the ASTCT framework grade CRS using hypotension and oxygen support?
In ASTCT 2019 consensus grading, fever of at least 38°C attributable to CRS establishes onset. Grade 1 has no hypotension or hypoxia. Grade 2 includes hypotension not requiring vasopressors, such as fluid-responsive hypotension, or low-flow nasal oxygen at no more than 6 L/min. Grade 3 includes one vasopressor with or without vasopressin, or high-flow nasal oxygen, facemask, nonrebreather, or Venturi oxygen. Grade 4 includes multiple vasopressors excluding vasopressin, or positive-pressure respiratory support. Use the more severe attributable domain. After antipyretic or anticytokine treatment, continued fever is unnecessary for grading ongoing CRS. The [2026 ASTCT consensus](https://www.astctjournal.org/article/S2666-6367%2826%2900363-5/fulltext) retains this framework with clarifications. Grading and product-specific treatment instructions are separate.
Apply it
A recipient whose fever resolves after treatment still requires one vasopressor and 3 L/min nasal oxygen. Attributable vasopressor use determines grade 3 despite the grade 2 oxygen requirement and absent current fever.
Common pitfall: Fever height and laboratory abnormalities do not determine the ASTCT CRS grade. Product labels may modify grading or treatment tables; do not silently mix those modifications with the consensus scale.
43.What subtle changes can signal early ICANS?
ICANS can begin with impaired attention, difficulty naming objects, altered handwriting, or expressive language changes before severe confusion develops. Compare findings with a documented baseline and assess serially. It may occur during CRS, after CRS resolves, or independently, so normal temperature and blood pressure do not exclude it. New neurologic findings require urgent evaluation for ICANS and other causes, including medication effects, metabolic disturbance, infection, or an acute neurologic event.
Apply it
A previously fluent patient becomes unable to name a familiar object and writes an unusually fragmented sentence after fever has resolved. Perform prompt structured neurologic assessment and escalate the change instead of attributing it to fatigue without further evaluation.
Common pitfall: Waiting for seizures or profound disorientation misses earlier language and attention changes. Resolution of CRS does not establish that the risk of neurologic toxicity has ended.
44.How should ICE findings be integrated with the full ICANS assessment?
The ICE assessment samples orientation, naming, command following, writing, and attention in appropriate patients. It is one part of ICANS grading, which also considers consciousness, seizures, motor findings, and cerebral edema or raised intracranial pressure. The most severe attributable feature determines the grade. A relatively preserved ICE result cannot neutralize a seizure, and a low result must be interpreted against baseline ability and competing causes. Age-appropriate assessment is necessary when ICE is unsuitable.
Apply it
An adult has an ICE score of 8 but experiences a brief generalized seizure attributed to ICANS that resolves promptly. Escalate according to the seizure-defined severity rather than using the ICE score alone to describe the event as mild.
Common pitfall: ICE is not the entire grading system. Sedation, baseline communication limitations, and more severe neurologic domains must be considered before assigning an overall ICANS grade.
45.Why do CRS and isolated ICANS require different treatment reasoning?
Tocilizumab targets IL-6 receptor signaling and is used in appropriate CRS management, but it does not efficiently cross the blood-brain barrier and is not an effective treatment for isolated ICANS. Corticosteroids are central to treatment of clinically significant ICANS, with supportive care and seizure management as indicated. Concurrent syndromes require assessment of both. The nursing decision is to recognize the dominant current toxicity and communicate it accurately rather than automatically repeating the treatment used for prior fever.
Apply it
A patient whose CRS has resolved develops progressive aphasia without hypotension or hypoxia. Request urgent ICANS evaluation and the prescribed neurologic management pathway rather than assuming another dose of tocilizumab alone will address the new syndrome.
Common pitfall: A drug's effectiveness for systemic inflammatory toxicity does not establish effectiveness for isolated neurotoxicity. Concurrent CRS must be assessed rather than assumed from the treatment history.
46.Which CRS context, clinical trajectory, and laboratory pattern suggest IEC-HS?
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a hyperinflammatory syndrome attributable to immune effector cell therapy and distinct from CRS and ICANS. The September 2026 ASTCT definition specifies that IEC-HS consistently develops in patients with antecedent CRS or ongoing/resolving CRS. This CRS context is a defining feature. Separately, characteristic deterioration occurs after initial improvement or as CRS resolves. The ferritin criterion is above five times the upper limit of normal when baseline was normal, above five times baseline when baseline was abnormal at infusion, and/or a clinically rapid rise. Accompanying findings include new or worsening cytopenias, transaminitis, and coagulopathy with hypofibrinogenemia, often below 150 mg/dL or the laboratory lower limit. Assess infection, disease progression, and other competing explanations. See the [2026 ASTCT consensus](https://www.astctjournal.org/article/S2666-6367%2826%2900363-5/fulltext).
Apply it
After documented CRS initially improves, a recipient develops worsening cytopenias, transaminitis, fibrinogen of 110 mg/dL, and ferritin rising from an abnormal infusion baseline of 600 ng/mL to 6,000 ng/mL. The antecedent CRS establishes the required clinical context; deterioration after improvement and the combined laboratory abnormalities strongly suggest IEC-HS. Escalate promptly for assessment while investigating infection and other causes. Ferritin elevation alone does not establish the diagnosis.
Common pitfall: Do not treat antecedent or ongoing/resolving CRS as an optional recognition clue. Also distinguish that defining context from the characteristic deterioration after initial improvement. Product-label HLH/MAS terminology is broader than the consensus IEC-HS definition: HLH-like abnormalities accompanying severe CRS do not automatically establish a separate IEC-HS episode.
47.Why do prolonged cytopenias remain important after early cellular therapy toxicity resolves?
Cellular therapy recipients can have prolonged neutropenia, thrombocytopenia, or anemia after the acute inflammatory period. These deficits create continuing infection, bleeding, and oxygen-delivery concerns even when CRS and ICANS are absent. Follow serial counts, symptoms, transfusion needs, and the team's assessment of underlying causes. A single improving lineage does not establish global marrow recovery. Patient teaching must connect ongoing laboratory monitoring with actionable symptoms rather than presenting the end of early toxicity as complete recovery.
Apply it
Several weeks after CAR T infusion, a patient feels better but reports new petechiae and remains neutropenic. Review counts and bleeding findings, reinforce urgent infection reporting, and maintain follow-up rather than reducing surveillance because the initial CRS has resolved.
Common pitfall: The absence of current CRS does not make persistent cytopenia benign. Early inflammatory recovery and hematologic recovery occur on different timelines and require separate assessment.
48.How does CD19-directed therapy cause B-cell aplasia and low immunoglobulins?
CD19-directed CAR T cells can attack normal B cells because these cells share the therapeutic target with the malignancy. B-cell aplasia can therefore lead to reduced immunoglobulin production and impaired humoral protection. Follow immunoglobulin measurements and infection history, with prevention and replacement treatment as directed. Normal neutrophil recovery does not correct this distinct deficit. The mechanism is target-related normal-cell depletion, not necessarily evidence of recurrent leukemia or failure of the original cellular product.
Apply it
A patient treated with tisagenlecleucel has normal neutrophils but recurrent respiratory infections and low immunoglobulins. Explain the possible target-related B-cell effect and arrange review of immune monitoring and supportive treatment rather than dismissing infection risk because the ANC is normal.
Common pitfall: B-cell aplasia is not equivalent to neutropenia. A normal complete blood count can coexist with clinically important antibody deficiency after CD19-directed therapy has been administered.
49.How should vaccination decisions account for immune recovery after CAR T therapy?
Vaccination after cellular therapy must account for immune deficits and the specific product's guidance. The tisagenlecleucel label advises against live vaccines for at least six weeks before lymphodepleting chemotherapy, during treatment, and until immune recovery afterward. A calendar interval or normal neutrophil count alone does not establish that recovery. Antibody deficiency and immunoglobulin treatment can also affect vaccine response or timing, so distinguish the safety concern of live organisms from the effectiveness of non-live vaccination.
Apply it
A patient with ongoing B-cell aplasia requests a live travel vaccine several months after tisagenlecleucel. Review the product precautions and immune status with the treating team before vaccination, explaining why elapsed time alone cannot establish eligibility.
Common pitfall: Do not automatically apply an HSCT vaccination calendar to every CAR T recipient. Treatment mechanism, immune recovery, and product-specific live-vaccine restrictions require separate consideration.
KYMRIAH: Package Insert and Medication Guide · Altered Immunocompetence
50.Why must neurologic follow-up continue beyond the initial ICANS period?
Neurologic effects after cellular therapy are not limited to the usual early ICANS presentation. Delayed movement or neurocognitive changes, including parkinsonism, have been reported after ciltacabtagene autoleucel. New gait changes, slowed movement, altered behavior, or cognitive decline deserve assessment even after early monitoring has ended. Document the precise change and treatment history while considering alternative neurologic causes. Timing outside the early window should broaden the differential rather than end it.
Apply it
Weeks after ciltacabtagene autoleucel, a caregiver reports new shuffling gait and slowed responses. Arrange prompt clinical assessment and communicate the exact product and symptom timeline rather than reassuring the family that a previously normal early ICE assessment excludes treatment-related problems.
Common pitfall: A normal early neurologic assessment does not exclude later toxicity. Conversely, every delayed symptom is not automatically ICANS; the phenotype and alternative causes still matter.
Immune Effector Cell-Associated Neurotoxicity Syndrome · download
51.How should possible treatment failure be distinguished from persistent toxicity?
Symptoms and laboratory abnormalities after cellular therapy can reflect persistent toxicity, infection, or recurrent disease. Fatigue or cytopenia alone cannot identify which process is responsible. Compare the current trajectory with prior response assessments and obtain the disease-specific evaluation directed by the team. A strong initial response does not guarantee durable control, while a persistent adverse effect does not independently prove failure. Nursing assessment should describe objective changes without converting nonspecific findings into a definitive relapse diagnosis.
Apply it
A patient with persistent fatigue fears that CAR T therapy has failed, although no response assessment has been completed. Assess the fatigue and associated findings, explain the limits of symptom interpretation, and support the scheduled disease-specific evaluation.
Common pitfall: Neither severe early toxicity nor absence of CRS proves therapeutic success. Clinical response and toxicity are different outcomes that require their own assessment and follow-up.
KYMRIAH: Package Insert and Medication Guide · 2026 TCTCN™ Test Content Outline
52.Why is lifelong secondary malignancy surveillance relevant after CAR T treatment?
The tisagenlecleucel label warns that subsequent malignancies, including T-cell malignancies, can occur after treatment and directs lifelong monitoring for secondary malignancies. The clinical distinction is between ongoing safety surveillance and assessment of recurrence of the original cancer. New persistent findings deserve evaluation without assuming either diagnosis. Removal of a regulatory access program does not erase product warnings or long-term follow-up obligations. Education should make continuing surveillance understandable even when the original malignancy remains controlled.
Apply it
A patient in remission asks whether all cellular therapy follow-up can end now that early monitoring is complete. Explain the continuing need for disease and secondary malignancy surveillance and encourage reporting of new persistent symptoms rather than waiting for routine appointments.
Common pitfall: A regulatory reduction in access requirements does not establish elimination of late risks. Remission of the original disease also does not exclude a later, different malignancy.
KYMRIAH: Package Insert and Medication Guide · FDA Eliminates REMS for Autologous CAR T-cell Immunotherapies
Quality of Life8%
53.When can palliative care accompany transplant or cellular therapy?
Palliative care addresses symptoms, emotional distress, social burdens, spiritual concerns, and communication needs during serious illness. It can accompany treatment intended to cure or control disease and does not require that transplantation or cellular therapy stop. Referral is driven by needs, such as persistent pain, anxiety, or difficult decisions. The nursing opportunity is to identify burden early and connect supportive expertise with the primary treatment team, rather than reserving help for the final phase of life.
Apply it
A transplant candidate wants to continue treatment but has uncontrolled pain and severe anxiety. Explain how palliative care can support these needs alongside the planned transplant and ask the team to consider a concurrent referral.
Common pitfall: Equating palliative care with abandonment of disease-directed treatment can delay effective symptom support. Its involvement does not independently determine prognosis or require a hospice enrollment decision.
54.How can caregiver assessment expose gaps in a discharge plan?
A discharge plan depends on what the patient and caregiver can actually perform, not merely whether written instructions were provided. Assess understanding of urgent symptoms, medication tasks, transport, competing responsibilities, and access to help. Caregiver exhaustion can undermine an otherwise technically correct plan. Use teach-back and coordinated support to identify the specific task that needs reinforcement or assistance. This turns a vague statement about family support into a practical assessment of monitoring and access.
Apply it
A caregiver correctly repeats the medication schedule but admits they cannot stay awake for required observations and have no transport backup. Coordinate additional support and clarify the escalation plan before discharge rather than treating successful medication recall as complete readiness.
Common pitfall: The presence of a relative does not prove adequate caregiving capacity. Knowledge, availability, emotional burden, and practical resources require separate assessment and targeted support.
Palliative Care in Cancer · 2026 TCTCN™ Test Content Outline
55.Why should fertility counseling occur before gonadotoxic treatment?
Chemotherapy and radiation can damage reproductive organs or endocrine function, with temporary or permanent fertility effects. Alkylating agents can injure ovarian follicles, and high-dose treatment can increase risk. Discuss reproductive goals before treatment because preservation options may require advance planning. The patient's present relationship status or uncertainty about future children does not remove the need for information. Nursing care should support timely specialist referral and informed choice without promising preservation success or assuming that treatment can safely be delayed.
Apply it
A young adult due to start conditioning says they might want biological children later but feels uncomfortable raising the subject. Facilitate urgent fertility counseling before treatment begins so options and timing can be discussed within the cancer treatment plan.
Common pitfall: Waiting until treatment ends may remove available preservation options. Neither young age nor ongoing menstruation guarantees future fertility after a potentially gonadotoxic treatment exposure.
56.How should sexuality and spiritual concerns be explored without assumptions?
Sexuality and spiritual well-being involve personal priorities that may change during prolonged treatment and recovery. Ask permission to discuss concerns, use inclusive language, and distinguish physical symptoms from distress about identity, relationships, meaning, or belief. A patient's culture or appearance does not reliably identify what support they want. Individual assessment guides referral and symptom evaluation, while privacy and the patient's preferences determine who participates. Avoid treating survival-focused care as a reason to omit these concerns.
Apply it
A survivor reports avoiding intimacy but does not describe why. Offer a private, open discussion about discomfort, body changes, relationship concerns, and personal priorities, then arrange relevant support rather than assuming the problem is solely loss of sexual interest.
Common pitfall: Assuming that age, partnership status, or religious affiliation predicts needs can silence important concerns. Ask the individual what matters before choosing education or a referral.
2026 TCTCN™ Test Content Outline · Palliative Care in Cancer
57.How do changing goals of care guide survivorship and end-of-life support?
Goals of care connect treatment choices with the patient's priorities, acceptable burdens, and understanding of likely outcomes. These discussions can occur during active treatment and should be revisited when function, disease status, or preferences change. Palliative care supports communication throughout serious illness; hospice addresses a different phase centered on end-of-life needs. Nursing assessment should identify the patient's own goals and unresolved questions, allowing the team to align symptom treatment, family support, and future planning with those priorities.
Apply it
After recurrent disease, a patient says staying comfortable at home now matters more than another hospital admission. Communicate this preference to the team and support a goals discussion that addresses realistic treatment options, home support, and end-of-life services if appropriate.
Common pitfall: Previous consent to intensive treatment is not a permanent statement of current goals. Reassessment should respect changing preferences without assuming that family members speak for a capable patient.
Palliative Care in Cancer · 2026 TCTCN™ Test Content Outline
Professional Performance4%
58.What makes research consent an ongoing voluntary process?
Research consent requires understandable information about purpose, procedures, risks, potential benefits, alternatives, and participant rights. Signing records agreement but does not surrender the right to leave a study. New questions or safety information may require renewed discussion during participation. Nursing advocacy includes recognizing uncertainty, supporting questions, and avoiding pressure based on family wishes or therapeutic urgency. A signed form does not establish that every later procedure remains understood or voluntarily accepted by the participant.
Apply it
Before a study-specific procedure, a participant says they no longer want to continue despite previously signing consent. Pause the research activity, clarify their wishes, and contact the study team rather than treating the earlier signature as irrevocable authorization.
Common pitfall: Consent is not a binding promise to complete research. A signature cannot replace ongoing understanding, voluntary participation, or attention to a participant's current decision.
59.Which occupational precautions must remain intact during process improvement?
Handling human cellular products requires universal precautions and product-specific biosafety procedures: use gloves, protect eyes and clothing when splashing is possible, dispose of sharps safely, contain spills, and report exposures promptly. Genetically modified cells still require careful handling and disposal. Aerosolized supportive medicines create different hazards. For nebulized pentamidine, eviQ recommends adequate ventilation, ideally negative pressure, exposure-minimizing equipment and procedures, full preparation PPE including a P2 or N95 respirator, and avoiding remaining in the room throughout treatment. See the [eviQ pentamidine precautions](https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/220-pneumocystis-jirovecii-pneumonia-pjp-prophyl). Quality improvement should measure delays and near misses while preserving identity checks, worker protection, and authorized handling.
Apply it
A proposal would move nebulized pentamidine into an unventilated treatment bay to save time. Address the aerosol exposure hazard and arrange appropriate controls rather than accepting a shorter appointment as evidence of a safer process.
Common pitfall: A surgical mask is not interchangeable with a specified respirator. Likewise, a replication-incompetent vector does not remove the need for universal precautions when handling human cells.
60.How does the FDA's CAR T REMS change affect continuing safety responsibilities?
In June 2025, FDA eliminated REMS for the specified approved BCMA- and CD19-directed autologous CAR T products. This removed that particular restricted-program requirement; it did not eliminate CRS, neurologic toxicity, or secondary malignancy risks. Accreditation, regulatory access programs, institutional standards, and product labeling serve different functions. Use current product instructions for monitoring and emergency readiness, and distinguish them from historical REMS requirements rather than assuming that one policy change replaces every other safety obligation.
Apply it
An outdated teaching slide says all listed autologous CAR T products still require the former FDA REMS certification. Update the statement using the FDA communication while retaining the current label-based monitoring, emergency preparation, and long-term surveillance education.
Common pitfall: REMS removal is not proof that treatment risks disappeared. Likewise, an accreditation framework and a discontinued product access restriction are not interchangeable regulatory concepts.
FDA Eliminates REMS for Autologous CAR T-cell Immunotherapies · KYMRIAH: Package Insert and Medication Guide
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give each of the four 22% domains substantial study time; reserve deliberate review for Quality of Life and Professional Performance rather than omitting them.
- Compare donor relationship, cell source, therapeutic target, and treatment purpose before predicting complications.
- Practise paired distinctions: HLA versus ABO, leukocyte reduction versus irradiation, acute versus chronic GVHD phenotype, and CRS versus ICANS.
- Use serial physiologic changes and named grading criteria to recognize deterioration; infection can coexist with inflammatory toxicity and can occur without fever.
- Learn product-specific verification and handling principles, including why living therapeutic cells require different administration practices from supportive blood components.
- Connect follow-up with antimicrobial coverage, pulmonary function trends, caregiver capacity, vaccination eligibility, occupational precautions, and lifelong surveillance.
A practical preparation plan
1. Map the complete blueprint
Use the official 2026 outline to mark every topic as confident, uncertain, or unfamiliar. Use these 60 concepts as a focused teaching set, then add study for outline topics that receive less detail here.
2. Build mechanism comparisons
Explain aloud how autologous HSCT, allogeneic HSCT, CAR T cells, TIL, DLI, NK cells, bispecific antibodies, and gene therapies work. For each, identify the administered material, intended effect, and a complication that follows from the mechanism.
3. Rehearse administration decisions
Walk through collection purpose, recipient readiness, identity reconciliation, preparation, infusion observation, and reaction response. Compare therapeutic-cell handling with supportive-transfusion selection and use the specific product instructions to resolve differences.
4. Practise complication discrimination
Compare neutropenic fever, afebrile sepsis, late acute versus chronic GVHD, SOS/VOD, BOS, CRS grades, ICANS, and IEC-HS. Name the decisive findings, the applicable criteria, and the competing explanations that require assessment.
5. Complete and analyze the learning test
Answer all 20 questions before reviewing explanations. For every error, write why the correct option fits the decisive cue and why the tempting alternative does not. Revisit the underlying concept rather than memorizing option positions.
6. Use spaced recall and close scope gaps
Review flashcards across several sessions and explain the reasoning without looking. Return to the complete outline for remaining gaps, then verify current exam arrangements and product-specific clinical updates in the relevant official references.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ONCC Changing Name of BMTCN® Certification to TCTCN™
- BMTCN® to TCTCN™ Name Change FAQ
- Transplantation and Cellular Therapy Certified Nurse (TCTCN™)
- 2026 TCTCN™ Test Content Outline
- 2026 ONCC Test Registration Manual
- Stem Cell and Bone Marrow Transplants for Cancer
- Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
- T-cell Transfer Therapy
- Peripheral Blood Stem Cell Donation Process Overview
- KYMRIAH: Package Insert and Medication Guide
- Hypersensitivity Reaction to Dimethyl Sulfoxide (DMSO)
- Neutropenic Fever: Patient Evaluation, Risk Assessment and Immediate Management
- EBMT–NIH–CIBMTR Task Force Position Statement on Standardized Terminology and Guidance for GVHD Assessment
- Sinusoidal Obstruction Syndrome Associated with Anti-cancer Therapy
- Altered Immunocompetence
- Cytokine Release Syndrome
- Immune Effector Cell-Associated Neurotoxicity Syndrome
- FDA Eliminates REMS for Autologous CAR T-cell Immunotherapies
- Palliative Care in Cancer
- Female Fertility and Cancer
- Understanding Informed Consent Forms
- download
- What is Gene Therapy? | FDA
- Therapeutic apheresis | Professional Education
- download
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA
- 220-Pneumocystis jirovecii pneumonia (PJP) prophylaxis in immunocompromised adults | eviQ
- 1795-Herpes simplex (HSV) and varicella zoster virus (VZV) prophylaxis in immunocompromised adults | eviQ
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report - PMC
- ASCIA Guidelines - Acute Management of Anaphylaxis - Australasian Society of Clinical Immunology and Allergy (ASCIA)
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.